IIM
MACK

Ipswich Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Ipswich Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-254
Closed -$14K – 373
2016
Q1 		$14K Buy
+254
New +$13.3K 0.01% 312

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Ipswich Investment Management's MACK Position: Q2 2016 in Review

Ipswich Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2016, closing a stake of 254 shares — an estimated $14K sold.

Ipswich Investment Management first reported a position in MACK in Q1 2016 and held it in 1 quarter. The position peaked at $14K in Q1 2016. 140 funds tracked by Wall St. Rank hold MACK as of Q2 2016.

  • Ipswich Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Ipswich Investment Management sold 254 Merrimack Pharmaceuticals, Inc. shares in Q2 2016, an estimated $14K.
  • Ipswich Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Ipswich Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $14K in Q1 2016.
  • 140 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2016.

Based on Ipswich Investment Management's 13F filing for Q2 2016, filed 2 Aug 2016.